Stay updated on Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial

Sign up to get notified when there's something new on the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The clinical trial page now displays the study record for a Phase 2 melanoma trial, including its treatment comparison, eligibility requirements, study locations, and outcome measures, rather than a forbidden-access error.
    Difference
    58%
    Check dated 2026-11-07T11:26:00.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-31T10:44:46.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-24T11:08:10.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T11:39:35.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1, while the study record page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T12:38:42.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a minimal header and footer, replacing the study record content and indicating the page is inaccessible.
    Difference
    19%
    Check dated 2026-09-19T19:16:13.000Z thumbnail image

Stay in the know with updates to Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page.